ArticleCancer2026
Breast cancer staging for patients with "low-risk" disease: Are they all the same?
Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundContemporary breast cancer staging incorporates anatomic and biologic factors. Although a low (<11) Oncotype Recurrence Score (RS) is linked to favorable survival, it is unclear if RS alone justifies downstaging to pathologic prognostic stage (PPS) IA. This study evaluated whether a low RS equates prognostically to PPS IA.
methodsPatients (18-75 years) with pT1-3/pN0-1/M0, hormone receptor-positive, HER2-negative unilateral invasive breast cancer, diagnosed between 2010 and 2018 were identified from the National Cancer Database. Patients receiving neoadjuvant therapy or lacking RS data were excluded. Patients were grouped by PPS, with overall survival (OS) estimated using Kaplan-Meier and adjusted with Cox models.
resultsAmong 231,031 patients, 23.8% had RS < 11, 36.6% had RS 11-17, 25.8% had RS 18-25, and 13.8% had RS > 25. Median follow up was 58.9 months. Most with RS < 11 were PPS IA (94.2%), yet OS declined with higher stage (p < .001). Adjusted analyses showed worse OS for higher stages within RS < 11 (IB: HR 1.66 [95% CI, 1.34-2.05]; IIA: HR 2.29 [1.44-3.65]; IIB: HR 2.48 [1.03-5.95]). In the RS 11-17 group, 90.8% were PPS IA. Five-year OS varied (IA: 97.8%, IB: 95.8%, IIA: 95.2%, IIB: 93.7%, IIIA: 100%; p < .001). Adjusted OS differences persisted (IB: HR 1.51 [1.32-1.73]; IIA: HR 1.32 [1.01-1.72]; IIB: HR 1.58 [0.95-2.63]; IIIA: HR 1.44 (0.21-9.95]).
conclusionsPrognostic stage significantly influences survival among patients with low RS. RS < 11 alone should not automatically downstage patients to PPS IA; anatomic and other nongenomic factors remain important for prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.